EPILEPSY IN PATIENTS WITH SUPRATENTORIAL MENINGIOMAS
Abstract
Meningiomas are the most common primary intracranial tumors. They are mostly slow-growing and of benign histopathology rendering them curable by surgery alone. Symptomatic lesions depend on the location with signs of focal neurological deficits or increased intracranial pressure. Seizures are the presenting symptoms in approximately 30% of supratentorial meningiomas. Epileptogenesis in these patients is not yet clearly defined. Epilepsy negatively affects the quality of life, limits independence, and impairs cognition, as well as increases the risk for psychiatric comorbidities including depression. Although surgical resection may offer seizure freedom in more than 60% of meningiomas, seizures persist after surgical resection in a significant number of patients. The potential preoperative and postoperative predictors for seizures in meningioma patients have been analyzed in multiple studies. Anti-seizure medications are employed in the treatment of these patients, however, their application is often followed by adverse neurocognitive side effects and inefficacy in some patients. Understanding various clinical, histopathological, and surgical factors potentially associated with epilepsy can help guide more effective seizure control and allow for better assessment of risk before and after surgery. Patients with persistent seizures may benefit from referral to an epilepsy center for evaluation.
References
1. Wiemels, J., M. Wrensch, and E.B. Claus, Epidemiology and etiology of meningioma. J Neurooncol, 2010. 99(3): p. 307-14.
2. Erturk Cetin, O., et al., Epilepsy-related brain tumors. Seizure, 2017. 44: p. 93-97.
3. Englot, D.J., et al., Seizures in supratentorial meningioma: a systematic review and meta-analysis. J Neurosurg, 2016. 124(6): p. 1552-61.
4. Chaichana, K.L., et al., Seizure control for patients undergoing meningioma surgery. World Neurosurg, 2013. 79(3-4): p. 515-24.
5. Tanti, M.J., et al., The impact of epilepsy on the quality of life of patients with meningioma: A systematic review. Br J Neurosurg, 2016. 30(1): p. 23-8.
6. Bauer, R., et al., Treatment of epileptic seizures in brain tumors: a critical review. Neurosurg Rev, 2014. 37(3): p. 381-8; discussion 388.
7. Baumgarten, P., et al., Focused review on seizures caused by meningiomas. Epilepsy Behav, 2018. 88: p. 146-151.
8. Cramer, J.A., et al., Adverse effects of antiepileptic drugs: a brief overview of important issues. Expert Rev Neurother, 2010. 10(6): p. 885-91.
9. Weller, R.O., et al., The meninges as barriers and facilitators for the movement of fluid, cells and pathogens related to the rodent and human CNS. Acta Neuropathol, 2018. 135(3): p. 363-385.
10. Chen, D.Y., et al., Tumor-related epilepsy: epidemiology, pathogenesis and management. J Neurooncol, 2018. 139(1): p. 13-21.
11. Fang, S., et al., Predictive value of electrocorticography for postoperative epilepsy in patients with supratentorial meningioma. J Clin Neurosci, 2013. 20(1): p. 112-6.
12. Hess, K., et al., Brain invasion and the risk of seizures in patients with meningioma. J Neurosurg, 2018. 130(3): p. 789-796.
13. Shamji, M.F., E.C. Fric-Shamji, and B.G. Benoit, Brain tumors and epilepsy: pathophysiology of peritumoral changes. Neurosurg Rev, 2009. 32(3): p. 275-84; discussion 284-6.
14. Islim, A.I., et al., The role of prophylactic antiepileptic drugs for seizure prophylaxis in meningioma surgery: A systematic review. J Clin Neurosci, 2017. 43: p. 47-53.
15. Lu, V.M., et al., Four Independent Predictors of Postoperative Seizures After Meningioma Surgery: A Meta-Analysis. World Neurosurg, 2019. 130: p. 537-545 e3.
16. Schutze, S., I.J. Orozco, and T.J. Jentsch, KCNQ Potassium Channels Modulate Sensitivity of Skin Down-hair (D-hair) Mechanoreceptors. J Biol Chem, 2016. 291(11): p. 5566-5575.
17. Ranade, S.S., R. Syeda, and A. Patapoutian, Mechanically Activated Ion Channels. Neuron, 2015. 87(6): p. 1162-1179.
18. Chen, W.C., et al., Factors Associated With Pre- and Postoperative Seizures in 1033 Patients Undergoing Supratentorial Meningioma Resection. Neurosurgery, 2017. 81(2): p. 297-306.
19. Lieu, A.S. and S.L. Howng, Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors. Epilepsy Res, 2000. 38(1): p. 45-52.
20. Islim, A.I., et al., Postoperative seizures in meningioma patients: improving patient selection for antiepileptic drug therapy. J Neurooncol, 2018. 140(1): p. 123-134.
21. Morsy, M.M., et al., Predictive Factors for Seizures Accompanying Intracranial Meningiomas. Asian J Neurosurg, 2019. 14(2): p. 403-409.
22. Wang, Y.C., et al., Seizures in surgically resected atypical and malignant meningiomas: Long-term outcome analysis. Epilepsy Res, 2018. 140: p. 82-89.
23. Li, X., et al., Risk factors and control of seizures in 778 Chinese patients undergoing initial resection of supratentorial meningiomas. Neurosurg Rev, 2020. 43(2): p. 597-608.
24. Xue, H., et al., Long-term control and predictors of seizures in intracranial meningioma surgery: a population-based study. Acta Neurochir (Wien), 2018. 160(3): p. 589-596.
25. Seyedi, J.F., C.B. Pedersen, and F.R. Poulsen, Risk of seizures before and after neurosurgical treatment of intracranial meningiomas. Clin Neurol Neurosurg, 2018. 165: p. 60-66.
26. Beghi, E., et al., Recommendation for a definition of acute symptomatic seizure. Epilepsia, 2010. 51(4): p. 671-5.
27. Baumgarten, P., et al., Early and Late Postoperative Seizures in Meningioma Patients and Prediction by a Recent Scoring System. Cancers (Basel), 2021. 13(3).
28. Wirsching, H.G., et al., Predicting outcome of epilepsy after meningioma resection. Neuro Oncol, 2016. 18(7): p. 1002-10.
29. Zheng, Z., et al., Early and late postoperative seizure outcome in 97 patients with supratentorial meningioma and preoperative seizures: a retrospective study. J Neurooncol, 2013. 114(1): p. 101-9.
30. Connolly, I.D., et al., Craniotomy for Resection of Meningioma: An Age-Stratified Analysis of the MarketScan Longitudinal Database. World Neurosurg, 2015. 84(6): p. 1864-70.
31. Raza, S.M., et al., Perioperative and long-term outcomes from the management of parasagittal meningiomas invading the superior sagittal sinus. Neurosurgery, 2010. 67(4): p. 885-93; discussion 893.
32. Hamasaki, T., et al., Higher incidence of epilepsy in meningiomas located on the premotor cortex: a voxel-wise statistical analysis. Acta Neurochir (Wien), 2012. 154(12): p. 2241-9.
33. Das, R.R., et al., Outcomes after discontinuation of antiepileptic drugs after surgery in patients with low grade brain tumors and meningiomas. J Neurooncol, 2012. 107(3): p. 565-70.
34. Komotar, R.J., et al., Prophylactic antiepileptic drug therapy in patients undergoing supratentorial meningioma resection: a systematic analysis of efficacy. J Neurosurg, 2011. 115(3): p. 483-90.
35. Walbert, T., et al., SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol, 2021. 23(11): p. 1835-1844.
36. Zhang, B., et al., Assessment of risk factors for early seizures following surgery for meningiomas using logistic regression analysis. J Int Med Res, 2011. 39(5): p. 1728-35.
37. Glantz, M.J., et al., Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2000. 54(10): p. 1886-93.
38. van der Meer, P.B., et al., Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members. Neurooncol Pract, 2022. 9(2): p. 105-113.